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ate the efficacy and safety of new anticoagulants in the treatment of AF. Methods: 
Health Technology Assessment of multiple technologies. We searched the electronic 
databases Cochrane Library, CRD, Pubmed, Embase and Lilacs, to search for the best 
available evidence assessing the new oral anticoagulants, compared with warfa-
rin in patients with AF. Results: Three randomized controlled trials evaluating 
dabigatran (110mg e 150mg), rivaroxaban 20mg and apixaban 5mg were included, 
all of them compared with warfarin. In this regard, dabigatran 110mg was associ-
ated with similar rates of stroke or systemic embolism and with a 20% relative risk 
reduction (RRR) of major hemorrhage compared with warfarin. Dabigatran 150mg 
was associated with a 34% RRR of stroke or systemic embolism and similar rates 
of major hemorrhage. Rivaroxaban 20mg was associated with similar rates of the 
primary efficacy and safety outcomes. Finally, apixaban was associated with a 21% 
RRR of stroke or systemic embolism and with 31% RRR of major bleeding compared 
with warfarin. ConClusions: There is strong evidence supporting these new tech-
nologies, especially regarding safety. Further studies are needed to support decision 
making, especially with regards to cost-effectiveness issues.
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objeCtives: Positron Emission Tomography (PET) might be useful for cancer staging 
and follow-up. The objetive was to assess the available evidence on efficacy, safety 
and coverage policies for use of PET in oncology. Methods: A bibliographic search 
was carried in PubMed, DARE, NHS EED, in health technology assessment (HTA) 
agencies and health insurers. Priority was given to systematic reviews; randomized 
clinical trials (RCTs); HTA; clinical practice guidelines (CPGs) and coverage policies 
(CPs). Results: Thirty-seven systematic reviews, 3 RCTs and 32 observational stud-
ies, 51 CPGs, 15 HTAs and 28 CPs were included. Breast Cancer (17 studies):There 
is no evidence of its use as routine practice. Some CPGs and CPs recommend it for 
suspicious images that could not be clarified through conventional studies. PET is 
not recommended for axillary staging or neodadyuvant response prediction. Lung 
Cancer (44 studies):The accuracy for lung nodule is similar to conventional methods. 
Most CPGs do not recommend the use of PET for lung cancer staging except in some 
non-small cell lung cancer with previous negative tests for metastasis. Colorectal 
Cancer (20 studies): There is no evidence of its use as routine practice. It might be 
used in patients with suspected recurrence and non-conclusive images. Genitourinary 
Tumors (70 studies): PET might be associated with changes in diagnosis or therapeutic 
only in specific cases, such as ovarian cancer with suspected recurrence and nor-
mal conventional images, in residual tumors due to seminoma and cervical cancer 
recurrence eligible for curative treatment. Primary Tumors of the Central Nervous 
System (15 studies):PET is not recommended as routine practice. CPGs, RCTs and CPs 
recognize its usefulness for differential diagnosis between relapse and radionecro-
sis. ConClusions: There is no evidence to support the use of PET in cancer patients 
as routine practice. At present, its use should be restricted to specific patients.
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objeCtives: To evaluate the efficacy, safety and cost-effectiveness data of lipid 
formulations of amphotericin B to establish which should be used for the treatment 
of systemic fungal infections in patients with HIV/AIDS in Brazil. Methods: We 
searched The Cochrane Library, Centre for Reviews and Dissemination, Tripdatabase, 
Medline and LILACS databases aiming to find systematic reviews (SRs) and eco-
nomic evaluations (EE) comparing liposomal amphotericin B (L-AmB) or ampho-
tericin B lipid complex (ABLC). Health Technology Assessments (HTA) were searched 
on agencies websites. Quality of the evidence and strength of recommendation 
were evaluated using the GRADE system. Results: We selected five SRs, in which 
one evaluated only safety data, and two economic evaluations. Four SRs were clas-
sified as poor quality and the strength of recommendation was considered weak 
in favor of L-AmB in all studies. In general there were no statistically significant 
differences in terms of survival and response to treatment (p< 0,05). However, L-AmB 
was associated with a lower risk of nephrotoxicity and increased serum creatinine. 
The two economic studies included had conflicting results. In the cost-minimization 
study there was no difference in total costs of the therapies, but the daily cost of 
acquisition and concomitant antifungal therapy and adverse events were lower 
for ABLC (0,002 and 0,027). The incremental cost-effectiveness analysis favored the 
L-AmB (€ 41734 vs. € 51724). Both studies showed important limitations and there 
were no studies considering the Brazilian context. ConClusions: Considering all 
the studies found, as well as their limitations, there is a lack of evidence to support 
the spread use of L-amB in patients with HIV/AIDS affected by fungal infections, 
unless strictly in cases where patients have abnormal renal function. Also, L-AmB 
could be used in case of intolerance to conventional amphotericin B.
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ernment in better health system performance, as well as the positive effect of 
increased public investment in health over the decade in health indicators and 
process insurance in the last 5 years. ConClusions: The results suggest a 
positive effect of central government spending on health and a negative effect 
of income inequality and margination index on maternal and infant mortali-
ties, clearly mediated by socioeconomic factors characteristic of each state. 
This methodological approach is proposed to evaluate the relationships of the 
different levels of functioning of a health system and the dynamics with the 
social determinants of these levels.
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objeCtives: As follow-up to prior work, investigate what evidence is required 
for reimbursement and prescribing of biosimilar drugs from four key therapy 
areas in six Latin American countries (Argentina, Brazil, Chile, Colombia, 
Mexico and Venezuela). Explore how these requirements may correspond to 
the regulatory pathways across the different countries. Methods: Conduct 
secondary research to determine any recent changes to biosimilar regulation in 
the six studied countries. Conduct targeted primary research with payers and 
physicians in the six counties exploring: 1) The therapy areas that payers and 
physicians consider most attractive for biosimilars; 2) The baseline evidence 
(bioequivalence, comparative trial data, extrapolation of indications, etc.) that 
stakeholders require across the key therapy areas and across countries; 3) The 
level of discount, below the branded equivalent, that payers and physicians 
would require to consider biosimilars for access or to prescribe to their patients; 
4) The expected access level and prescribing decisions for those biosimilars that 
meet these evidence and discount criteria; and 5) The degree to which payer 
and physician evidence expectations for biosimilars map to our understanding 
of the evolution of biosimilar regulatory environment. Results: Public payers 
across the region see biosimilars as an opportunity to provide broader access to 
needed medications, although some stakeholders are more receptive than oth-
ers and have lower requirements to prove comparability. Clinicians in general 
have concerns about safety and efficacy, however, their willingness to prescribe 
biosimilars correlates inversely with the degree of access and affordability of 
the branded agents. ConClusions: The regulatory and access environment for 
biosimilars in Latin America can be expected to be more favorable than in the 
US but not too dissimilar from Europe. However there are systematic differences 
across countries and therapy areas.
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objeCtivos: El Streptococcus pneumoniae causa una importante morbilidad y 
mortalidad a nivel mundial, tanto en niños como en adultos. El objetivo de este 
análisis es estimar la costo-efectividad de la vacuna conjugada 13-valente (PCV13) 
vs la vacuna neumocócica polisacárida 23-valente (PPSV23) y vs no vacunación en 
los adultos de alto riesgo (inmunocomprometidos) > 50 años en Colombia, desde 
la perspectiva del tercero pagador. MetodologíAs: Se adaptó un modelo de 
Markov con horizonte de tiempo de la expectativa de vida y tasa de descuento 3% 
anual. Los comparadores fueron PCV13, PPSV23 y no vacunación (NV), cobertura 
estimada del 70%; revacunación a los 5 años con PPSV23 para > 65 años según 
criterios del CDC. Se utilizó la población > 50 años de alto riesgo en Colombia. 
Las probabilidades de transición, incidencia de enfermedades y efectividades de 
las vacunas fueron extraídas de la literatura (para PCV13 se utilizaron datos de 
PCV7 ajustados por inmunosenescencia), los costos médicos fueron proveídos por 
una EPS de cobertura nacional; los precios de las vacunas fueron tomados de la 
OPS para 2013. Los costos se presentan en US$ 2013. Las medidas de efectividad 
fueron número de casos evitados de enfermedad neumocócica invasiva – ENI 
(meningitis y bacteremia), neumonía invasiva, muertes y años de vida ganados 
(AVG). ResultAdos: Vacunar con PCV13 vs NV y PPSV23 previene 4.389 y 4.134 
casos de ENI; 2594 casos de neumonía invasiva y 550 y 536 muertes respectiva-
mente. PCV13 genera 199 AVG más que PPSV23 y 4.712 AVG más que NV. El ahorro 
total esperado (vacunación + costos médicos) con PCV13 fue US$18,254,171 vs NV 
y US$26,204,251 vs PPSV23. ConClusiones: Vacunar adultos inmunocompro-
metidos > 50 años con PCV13 en Colombia es una alternativa costo-ahorradora en 
comparación con NV y con PPSV23 (US$12.57 y US$18.08 ahorrados por paciente 
respectivamente). Los hallazgos de este estudio soportan una toma de decisión 
a favor de PCV13.
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Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. 
Patients with AF have a 4-5 times larger risk of stroke than age-matched controls. 
Anticoagulation with warfarin is currently the standard of care but the requirement 
for routine monitoring and drug and food interactions, makes its use is suboptimal. 
New anticoagulants were developed to eliminate these barriers and the results are 
promising. However, the incorporation of these technologies within the Brazilian 
Unified Health System (SUS) demands proper consideration. objeCtives: To evalu-
